Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. NASDAQ /
  3. LPCN.NASDAQ

Lipocine Inc (LPCN NASDAQ) stock market data APIs

$6 0.49(8.9%) as of July 26, 2024
Price chart is built with Anychart

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Lipocine Inc Financial Data Overview

5.51
6
-
6
5.51
2.3101-11.79
31 125 K
5 348 K
4 711 K
0.66
1.117
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'LPCN',
Type: 'Common Stock',
Name: 'Lipocine Inc',
Exchange: 'NASDAQ',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG0029L1X69',
ISIN: NULL,
CUSIP: NULL,
CIK: '1535955',
EmployerIdNumber: '99-0370688',
FiscalYearEnd: 'December',
IPODate: '2013-10-22',
InternationalDomestic: 'Domestic',
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: 'Domestic',
IsDelisted: false,
}

Lipocine Inc Fundamental Data is available in our Financial Data APIs

  • Net Revenue 4 711 K
  • EBITDA -10 337 441
  • Earnings Per Share -1.72
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Lipocine Inc Earnings via APIs

  • Latest Release 2024-05-09
  • EPS/Forecast -0.68

Get Lipocine Inc End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Lipocine Inc latest news via APIs

LPCN: 1148 Shows Muscle Loss Reversal

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Lipocine Inc. (NASDAQ:LPCN) provided a pleasant surprise to investors with its strong Phase II results from its LPCN 1148 st...

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) Fewer hepatic encephalopathy (HE) events of grade >1 in the LPCN 1148 treatment...
Do you have any questions?
support@eodhistoricaldata.com